No major neurologic complications with sirolimus use in heart transplant recipients

Mayo Clinic Proceedings

Volumn 84, Issue 4, 2009, Pages 330-332

  Van De Beek, Diederik ^a   Kremers, Walter K ^a   Kushwaha, Sudhir S ^a   McGregor, Christopher G A ^a   Wijdicks, Eelco F M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEUROLOGICAL COMPLICATION; NEUROTOXICITY; POLYNEUROPATHY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; RETROSPECTIVE STUDY; SEIZURE; STATISTICAL ANALYSIS; STROKE; TRANSIENT ISCHEMIC ATTACK; TREMOR; VASCULAR DISEASE; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CHILD; MIDDLE AGED; NEUROLOGIC DISEASE; POSTOPERATIVE COMPLICATION; PSYCHOSIS;

ADOLESCENT; ADULT; CHILD; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; NERVOUS SYSTEM DISEASES; POSTOPERATIVE COMPLICATIONS; PSYCHOSES, SUBSTANCE-INDUCED; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 64749103991     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.4.330     Document Type: Article

References (14)

1. Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs. 2007;67(3):369-391. (Pubitemid 46425551)
2. Maramattom BV, Wijdicks EF. Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients. Neurology. 2004;63(10):1958-1959. (Pubitemid 39532403)
3. Moskowitz A, Nolan C, Lis E, Castro-Malaspina H, Perales MA. Posterior reversible encephalopathy syndrome due to sirolimus. Bone Marrow Transplant. 2007 May;39(10):653-654. Epub 2007 Mar 26. (Pubitemid 46722847)
4. Tsagalou EP, Anastasiou-Nana MI, Margari ZJ, Vassilopoulos D. Possible everolimus-induced, severe, reversible encephalopathy after cardiac transplantation. J Heart Lung Transplant. 2007;26(6):661-664. (Pubitemid 46818045)
5. Bodkin CL, Eidelman BH. Sirolimus-induced posterior reversible encephalopathy. Neurology. 2007;68(23):2039-2040. (Pubitemid 46869711)
6. van de Beek D, Kremers W, Daly RC, et al. Effect of neurologic complications on outcome after heart transplant. Arch Neurol. 2008;65(2):226-231.
7. Rapamune (sirolimus) [package insert]. Philadelphia, PA: Wyeth Laboratories; 2003. http://www.fda.gov/cder/foi/label/2004/21110scf018-rapamune- lbl.pdf. Accessed February 6, 2009.
8. Cleary C, Linde JA, Hiscock KM, et al. Antidepressive-like effects of rapamycin in animal models: implications for mTOR inhibition as a new target for treatment of affective disorders. Brain Res Bull. 2008 Jul;76(5):469-473. Epub 2008 Apr 3.
9. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol. 2008;65(2):205-210.
10. McCalmont V, Bennett K. Progressive multifocal leukoencephalopathy: a case study. Prog Transplant. 2007;17(2):157-160. (Pubitemid 46897066)
11. Molina MG, Diekmann F, Burgos D, et al. Sympathetic dystrophy associated with sirolimus therapy. Transplantation. 2008;85(2):290-292.
12. Collini A, De Bartolomeis C, Barni R, Ruggieri G, Bernini M, Carmellini M. Calcineurin-inhibitor induced pain syndrome after organ transplantation. Kidney Int. 2006 Oct;70(7):1367-1370. Epub 2006 Sep 6. (Pubitemid 44435191)
13. Poon M, Badimon JJ, Fuster V. Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. Lancet. 2002;359(9306):619-622. (Pubitemid 34178449)
14. Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation. 2007 Dec 4;116(23):2726-2733. Epub 2007 Nov 19. (Pubitemid 350291245)